Class information for:
Level 1: ORPHAN DRUGS//RARE DISEASES//OFF ORPHAN PROD DEV

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
17331 541 27.5 48%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1294 8163 FOOD AND DRUG LAW JOURNAL//GENERIC SUBSTITUTION//DIRECT TO CONSUMER ADVERTISING

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ORPHAN DRUGS Author keyword 38 46% 12% 63
2 RARE DISEASES Author keyword 23 24% 16% 86
3 OFF ORPHAN PROD DEV Address 14 65% 2% 13
4 ORPHAN DRUG ACT Author keyword 9 64% 2% 9
5 ORPHAN DRUG Author keyword 9 33% 4% 22
6 ORPHAN MEDICINAL PRODUCTS Author keyword 6 100% 1% 4
7 RARE DISEASE Author keyword 5 15% 6% 33
8 ORPHAN MEDICINAL PRODUCT Author keyword 4 75% 1% 3
9 NEW DRUG LAUNCHES Author keyword 3 100% 1% 3
10 ORPHAN MEDICINES Author keyword 3 50% 1% 4

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ORPHAN DRUGS 38 46% 12% 63 Search ORPHAN+DRUGS Search ORPHAN+DRUGS
2 RARE DISEASES 23 24% 16% 86 Search RARE+DISEASES Search RARE+DISEASES
3 ORPHAN DRUG ACT 9 64% 2% 9 Search ORPHAN+DRUG+ACT Search ORPHAN+DRUG+ACT
4 ORPHAN DRUG 9 33% 4% 22 Search ORPHAN+DRUG Search ORPHAN+DRUG
5 ORPHAN MEDICINAL PRODUCTS 6 100% 1% 4 Search ORPHAN+MEDICINAL+PRODUCTS Search ORPHAN+MEDICINAL+PRODUCTS
6 RARE DISEASE 5 15% 6% 33 Search RARE+DISEASE Search RARE+DISEASE
7 ORPHAN MEDICINAL PRODUCT 4 75% 1% 3 Search ORPHAN+MEDICINAL+PRODUCT Search ORPHAN+MEDICINAL+PRODUCT
8 NEW DRUG LAUNCHES 3 100% 1% 3 Search NEW+DRUG+LAUNCHES Search NEW+DRUG+LAUNCHES
9 ORPHAN MEDICINES 3 50% 1% 4 Search ORPHAN+MEDICINES Search ORPHAN+MEDICINES
10 CONDITIONAL APPROVAL 3 60% 1% 3 Search CONDITIONAL+APPROVAL Search CONDITIONAL+APPROVAL

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 RARE DISEASES 17 28% 9% 51
2 ORPHAN DRUGS 12 38% 5% 25
3 ORPHAN DRUG ACT 3 100% 1% 3
4 EFFECTIVE DEPLOYMENT 2 67% 0% 2
5 HOUSE BELIEVES 2 67% 0% 2
6 CONCEPT HINDERS 1 100% 0% 2
7 MARKET EXCLUSIVITY 1 50% 0% 2
8 ORPHAN MEDICINAL PRODUCTS 1 100% 0% 2
9 NEGLECTED DISEASES 1 12% 2% 11
10 SAFETY PROBLEMS 1 40% 0% 2

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper 2015 3 19 32%
Orphan drugs: the regulatory environment 2013 8 3 100%
Orphan drug development: an economically viable strategy for biopharma R&D 2012 25 11 64%
Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010 2012 9 13 100%
Determinants for successful marketing authorisation of orphan medicinal products in the EU 2012 8 11 91%
Pricing and reimbursement of orphan drugs: the need for more transparency 2011 24 16 56%
The Italian National Plan for Rare Diseases 2014 2 1 100%
THE YEAR'S NEW DRUGS & BIOLOGICS, 2011 2012 4 1 100%
The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases 2014 1 2 100%
Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach 2013 3 12 75%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 OFF ORPHAN PROD DEV 14 65% 2.4% 13
2 RARE DIS THER IES 3 60% 0.6% 3
3 ITALIAN RARE DIS 2 67% 0.4% 2
4 EUROPEAN GAUCHER ALLIANCE 1 100% 0.4% 2
5 MED DEVICES COSMET 1 50% 0.4% 2
6 RARE DIS PROGRAM 1 50% 0.4% 2
7 SHIRE HUMAN GENET THER IES 1 100% 0.4% 2
8 OFF RARE DIS 1 11% 1.5% 8
9 DIRECT GEN OFFRE SOINS 1 50% 0.2% 1
10 DRUGS NEW BIOTECHNOL PROD 1 50% 0.2% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000197424 DRUG LAG//OFF PHARMACEUT IND//JAPANESE CLINICAL TRIALS
2 0.0000138339 CLINICAL TRIAL RISK//CONTINUOUS IMPROVEMENT//STRATEGIE IND
3 0.0000089595 HEALTH TECHNOLOGY ASSESSMENT//INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE//COVERAGE WITH EVIDENCE DEVELOPMENT
4 0.0000086814 COMPULSORY LICENSING//ACCESS TO MEDICINES//DOHA DECLARATION
5 0.0000081787 GENERIC SUBSTITUTION//GENERIC DRUGS//REFERENCE PRICING
6 0.0000078996 CREA GREEN//ECONOMICS OF ANTIBIOTIC RESISTANCE//GENERAT CONTRACTS
7 0.0000076842 CARDIOVASC METABOL SERV//FORMULARY DEV//SPECIALTY DRUGS
8 0.0000076575 PROGRAM LIFE SCI ETH POLICY//MCLAUGHLIN ROTMAN GLOBAL HLTH//ESRC INNOGEN
9 0.0000068139 DEVELOPMENT OF SOCIETIES//INDIGENOUS ACCREDITATION//MT ROMANCE
10 0.0000067963 NATIONAL IMMUNIZATION TECHNICAL ADVISORY GROUP NITAG//IMMUNIZATION FINANCING//PROVAC INITIAT